{"prompt": "['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 51 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'For the CRF, data must be derived from source documents, for example:', 'Patient identification: gender, year of birth (in accordance with local laws and', 'regulations)', 'Patient participation in the trial (substance, trial number, patient number, date patient', 'was informed)', \"Dates of patient's visits, including dispensing of trial medication\", 'Medical history (including trial indication and concomitant diseases, if applicable)', 'Medication history', 'Adverse events and outcome events (onset date (mandatory), and end date (if', 'available))', 'Serious adverse events (onset date (mandatory), and end date (if available))', 'Concomitant therapy (start date, changes)', 'Originals or copies of laboratory results and other imaging or testing results, with', 'proper documented medical evaluation (in validated electronic format, if available)', 'Completion of patient\\'s participation in the trial\" (end date; in case of premature', 'discontinuation document the reason for it).', 'Prior to allocation of a patient to a treatment into a clinical trial, there must be', 'documented evidence in the source data (e.g. medical records) that the trial participant', 'meets all inclusion criteria and does not meet any exclusion criteria. The absence of', 'records (either medical records, verbal documented feedback of the patient or testing', 'conducted specific for a protocol) to support inclusion/exclusion criteria does not make', 'the patient eligible for the clinical trial.', '8.3.2', 'Direct access to source data and documents', 'The sponsor will monitor the conduct of the trial by regular on-site monitoring visits and in-', 'house data quality review. The frequency of site monitoring will be determined by assessing', 'all characteristics of the trial, including its nature, objective, methodology and the degree of', 'any deviations of the intervention from normal clinical practice.', 'The investigator /institution will allow site trial-related monitoring, audits, IRB / IEC review', 'and regulatory inspections. Direct access must be provided to the CRF and all source', 'documents/data, including progress notes, copies of laboratory and medical test results, which', 'must be available at all times for review by the CRA, auditor and regulatory inspector', '(e.g. FDA). They may review all CRFs and informed consents. The accuracy of the data will', 'be verified by direct comparison with the source documents described in section 8.3.1. The', 'sponsor will also monitor compliance with the protocol and GCP.', 'An adaptive approach to clinical trial monitoring will be utilised. This is initiated by an', 'assessment of the risk associated with the trial combined with identification of critical data', 'and processes. An Integrated Quality and Risk Management Plan documents the strategies', 'involved with the implementation of onsite, offsite and central monitoring activities in order', 'to direct focus to the areas of greatest risk which have the most potential impact to patient', 'safety and data quality. Trial oversight is achieved by regular review of a report of risk which', 'then influences any monitoring adaptations.', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 52 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'The investigator /institution will allow on-site trial-related monitoring, audits, IRB/IEC', 'review and regulatory inspections. Direct access should be granted to all source documents', '(paper and e-records) including progress notes, copies of laboratory and medical test results', 'The CRA and auditor may review all CRFs and informed consents. The accuracy of the data', 'will be verified by direct comparison with the source documents described in section', '8.3.1. The sponsor will also monitor compliance with the protocol and ICH GCP.', '8.3.3', 'Storage period of records', 'Trial site(s):', 'The trial site(s) must retain the source and essential documents (including ISF) according to', 'contract or the local requirements valid at the time of the end of the trial (whatever is longer).', 'Sponsor:', \"The sponsor must retain the essential documents according to the sponsor's SOPs.\", '8.4', 'EXPEDITED REPORTING OF ADVERSE EVENTS', 'BI is responsible to fulfil their legal and regulatory reporting obligation in accordance with', 'regulatory requirements.', '8.5', 'STATEMENT OF CONFIDENTIALITY AND PATIENT PRIVACY', 'Individual patient data obtained as a result of this trial is considered confidential and', 'disclosure to third parties is prohibited with the exceptions noted below. Patient privacy will', 'be ensured by using patient identification code numbers.', 'Data protection and data security measures are implemented for the collection, storage and', 'processing of patient data in accordance with the principles 6 and 12 of the WHO GCP', 'handbook.', \"Treatment data may be given to the patient's personal physician or to other appropriate\", \"medical personnel responsible for the patient's welfare. Data generated as a result of the trial\", \"need to be available for inspection on request by the participating physicians, the sponsor's\", 'representatives, by the IRB / IEC and the regulatory authorities.', '8.5.1', 'Collection, storage and future use of biological samples and corresponding', 'data', 'Measures are in place to comply with the applicable rules for the collection, storage and', 'future use of biological samples from clinical trial participants and the corresponding data, in', 'particular', 'A Quality Management System has been implemented to ensure the adherence with', 'the Principles of Good Clinical Practice as outlined in \"Note For Guidance On Good', \"Clinical Practice' (CPMP/ICH/13 5/95)\", 'The BI-internal facilities storing and analysing biological samples and data from', \"clinical trial participants as well as the laboratories' activities for clinical trials\", 'sponsored by Boehringer Ingelheim are regularly audited. The analytical groups and', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']\n\n###\n\n", "completion": "END"}